RxDoctor Payments Data

Yun-Wei Chang

Acute Care · Milton, FLNPI 1255708459

Payments from drug & device makers

$3,537in general payments, 2019–2025

Across 222 payments — averaging $15.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$920
  • AbbVie$422
  • GSK$344
  • Bayer$298
  • Dexcom, Inc.$246
  • Otsuka America Pharmaceutical, Inc.$205
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$3,537100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,537 in reported general payments places this provider in the 90th percentile of 1,150 acute care providers in Florida.

See all acute care providers in Florida

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide48$56,688
RybelsusSemaglutide46$54,067
FarxigaDapagliflozin Propanediol54$46,550
OzempicSemaglutide38$44,020
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$43,323
Breztri AerosphereBudesonide/Glycopyr/Formoterol58$42,401
EliquisApixaban41$40,561
LinzessLinaclotide43$34,741
VraylarCariprazine Hcl19$29,313
JanuviaSitagliptin Phosphate26$23,322
TrulicityDulaglutide23$22,099
MyrbetriqMirabegron36$20,056
VascepaIcosapent Ethyl21$10,013
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$4,003
Albuterol Sulfate HfaAlbuterol Sulfate142$3,708

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$920$98,08784 claims
AstraZenecaFarxiga, Breztri Aerosphere$195$88,950112 claims
Lilly USA, LLCMounjaro, Trulicity$130$78,78771 claims
AbbVieLinzess, Vraylar$422$64,05562 claims
GSKTrelegy Ellipta$344$43,32352 claims
PfizerEliquis$88$40,56141 claims
MerckJanuvia$12$23,32226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,150 acute care providers in Florida.

Other acute care in Milton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →